Yeast as a Model for Neurodegenerative Disease?

January 26, 2015 | Yumanity, a well-connected drug discovery startup, plans to play the long game in drug development by using yeast models in deep phenotypic screens to study neurological diseases based on protein misfolding. The discovery platform is the brainchild of Susan Lindquist, scientific founder and previously the co-founder of FoldRx, who contends that yeast shares enough biology with humans to explore the molecular pathways surrounding protein misfolding events, while offering better opportunities to dig into those pathways in depth. Yumanity is also led by CEO Tony Cole and CSO Kenneth Rhodes, and has announced it has a novel target for Parkinson's disease. Xconomy